OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Hardesty, Melissa M.; Krivak, Thomas C.; Wright, Gail S.; Hamilton, Erika; Fleming, Evelyn; Belotte, J; Keeton, Erika Krasnickas; Wang, Ping; Gupta, Divya; Clements, Aine; Gray, Heidi J.; Konecny, Gottfried E.; Moore, Richard G.; Richardson, Debra L.

doi:10.1016/j.ygyno.2022.05.020

Cited by 35 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At SGO 2022, the latest data from the OVARIO trial were updated with sequential niraparib combined with bevacizumab maintenance therapy after first-line platinum-containing chemotherapy combined with bevacizumab in patients with newly diagnosed stage IIIB to IV OC, with an mPFS of 19.6 months at 28.7 months, respectively; immature OS data; and an OS event rate of 23.8%. This single-arm study demonstrated that first-line maintenance therapy with niraparib in combination with bevacizumab results in promising PFS outcomes regardless of the patient's biomarker profile (Hardesty et al, 2022).…”

Section: First-line Treatment With Niraparibmentioning

confidence: 80%

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Huang

Shan

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Currently, for ovarian cancer, which has the highest mortality rate among all gynecological cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by platinum-based combination chemotherapy. Although the survival rate after standard treatment has improved, the therapeutic effect of traditional chemotherapy is very limited due to problems such as resistance to platinum-based drugs and recurrence. With the advent of the precision medicine era, molecular targeted therapy has gradually entered clinicians’ view, and individualized precision therapy has been realized, surpassing the limitations of traditional therapy. The detection of genetic mutations affecting treatment, especially breast cancer susceptibility gene (BRCA) mutations and mutations of other homologous recombination repair defect (HRD) genes, can guide the targeted drug treatment of patients, effectively improve the treatment effect and achieve a better patient prognosis. This article reviews different sites and pathways of targeted therapy, including angiogenesis, cell cycle and DNA repair, and immune and metabolic pathways, and the latest research progress from preclinical and clinical trials related to ovarian cancer therapy.

show abstract

Section: First-line Treatment With Niraparibmentioning

confidence: 80%

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Huang

Shan

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Regarding the combination maintenance therapy of niraparib with bevacizumab, its safety in newly diagnosed advanced ovarian cancer was assessed in the OVARIO study which was a phase II, single-arm, open-label trial that showed promising results and safety profiles consistent with those known from bevacizumab and niraparib monotherapy [17]. The phase III trial, which aims to compare the efficacy of the niraparib monotherapy maintenance with combined niraparib and bevacizumab maintenance therapy in patients with FIGO III/IV (except FIGO stage IIIA2 without nodal involvement) ovarian cancer regardless of BRCA status and debulking surgery outcome, is about to start recruitment (NCT05009082).…”

Section: Clinical Efficacy Of Niraparibmentioning

confidence: 99%

Niraparib maintenance in newly diagnosed advanced ovarian cancer — review and case series

Tyszka

Stec

2023

Oncol Clin Pract

View full text Add to dashboard Cite

Introducing PARP inhibitors maintenance therapy into clinical practice significantly improved treatment outcomes in patients with high-grade platinum-sensitive advanced ovarian cancer, the most lethal gynecological malignancy.Niraparib is a potent PARP inhibitor whose safety and efficacy were assessed in the placebo-controlled, randomized clinical trial PRIMA. Niraparib significantly prolonged progression-free survival in the overall population of high-grade advanced ovarian cancer regardless of BRCA and homologous deficiency status compared to placebo. However, the most significant benefit was observed in BRCA mutated and homologous recombination deficient subgroups. Niraparib has a manageable toxicity profile and is well-tolerated by patients. Most common toxicities are hematological and can be managed with drug interruption and dose reduction that do not decrease efficacy. Niraparib is recommended for patients who responded to the first-line chemotherapy with platinum compound regardless of homologous recombination status. This review will discuss the use of niraparib in newly diagnosed advanced ovarian cancer patients focusing on its efficacy and tolerability. Additionally, a case series will be presented to further discuss this drug use in clinical practice in Poland.

show abstract

“…Niraparib has also been combined with bevacizumab in the primary maintenance setting in a Phase II single-arm study 47 including patients post-optimal debulking surgery. Analysis at 18 months showed PFS rates of 62% in the overall population, 76% in HRD and 47% in HR proficient groups.…”

Section: Clinical Studies Of Parp Inhibitors In Ovarian Cancersmentioning

confidence: 99%

“…The combination of olaparib with bevacizumab had an acceptable toxicity profile with no significant deterioration in quality-of-life analyses. 46 Niraparib has also been combined with bevacizumab in the primary maintenance setting in a Phase II single-arm study 47 including patients post-optimal debulking surgery. Analysis at 18 months showed PFS rates of 62% in the overall population, 76% in HRD and 47% in HR proficient groups.…”

Section: Parp Inhibitors As Primary Maintenance Therapymentioning

confidence: 99%

Towards Personalized Management of Ovarian Cancer

Algethami¹,

Kulkarni²,

Sadiq³

et al. 2022

CMAR

View full text Add to dashboard Cite

Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60–80%, most patients will have recurrence and succumb to the disease. However, a DNA repair–directed precision medicine strategy has recently generated real hope in improving survival. The clinical development of PARP inhibitors has transformed lives for many patients with BRCA germline-deficient and/or platinum-sensitive epithelial ovarian cancers. Antiangiogenic agents and intraperitoneal chemotherapy approaches may also improve outcomes in patients. Moreover, evolving immunotherapeutic opportunities could also positively impact patient outcomes. Here we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in ovarian cancer.

show abstract

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Cited by 35 publications

References 21 publications

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Niraparib maintenance in newly diagnosed advanced ovarian cancer — review and case series

Towards Personalized Management of Ovarian Cancer

Contact Info

Product

Resources

About